Bradykinin is associated with infections and inflammation, which given the strong correlation between uterine infection and preterm labour may imply that it could play a role in this process. Therefore, we investigated bradykinin signalling, and the roles that arrestin proteins play in their regulation in human myometrial cells. Bradykinin induced rapid, transient intracellular Ca 2+ increases that were inhibited following B 2 receptor (B 2 R) antagonism.
Abstract
Bradykinin is associated with infections and inflammation, which given the strong correlation between uterine infection and preterm labour may imply that it could play a role in this process. Therefore, we investigated bradykinin signalling, and the roles that arrestin proteins play in their regulation in human myometrial cells. Bradykinin induced rapid, transient intracellular Ca 2+ increases that were inhibited following B 2 receptor (B 2 R) antagonism.
Arrestin2 or arrestin3 depletion enhanced and prolonged bradykinin-stimulated Ca 2+ responses, and attenuated B 2 R desensitization. Knockdown of either arrestin enhanced B 2 Rstimulated ERK1/2 signals. Moreover, depletion of either arrestin elevated peak-phase p38-MAPK signalling, yet only arrestin3 depletion prolonged B 2 R-induced p38-MAPK signals.
Arrestin2-knockdown augmented bradykinin-induced cell movement. Bradykinin stimulates pro-contractile signalling mechanisms in human myometrial cells and arrestin proteins play key roles in their regulation. Our data suggest bradykinin not only acts as an utertonin, but may have the potential to enhance the contractile environment of the uterus.
Graphical abstract
Bradykinin-stimulates pro-contractile signalling pathways in human myometrial smooth muscle cells which induces cellular movement. The bradykinin-activated signalling pathways regulated by arrestin proteins are shown alongside potential pathways by which bradykinin may induce a pro-contractile phenotype through MAPK signalling are displayed as '?'.
Introduction
Bradykinin is a member of the kinin family, potent pro-inflammatory peptides which are stored as precursor peptides in the plasma membranes of cells (Blaes et al., 2013) . Kinins are liberated into the circulation following cleavage by serine proteases called kallikreins, a process that is greatly enhanced during bacterial infections (Blaes et al., 2013) . Interestingly, the presence of the kallikein-kinin system in the human endometrium and myometrium (Clements et al., 1994) , suggests that the uterus has the capacity to produce pro-inflammatory agents such as bradykinin in response to bacterial infections. Moreover, as there is a strong correlation between infection and preterm labour (Goldenberg et al., 2008) , and that bradykinin is known to induce myometrial contraction (Senior et al., 1976; Janicek et al., 2007) , it is possible that bradykinin signalling may play a part in the induction of myometrial contraction not only secondary to infectious stimuli, but also conceivably in the normal parturition process. Indeed, in rats it has been suggested that the actions of bradykinin are mediated through the bradykinin B 2 receptor (B 2 R) (Murone et al., 1999) , which recruits G q and/or G i to activate phospholipase C (PLC) and inhibit adenylyl, increasing intracellular ([Ca 2+ ] i ) and reducing cyclic AMP concentrations, respectively (Marceau et al., 1998; Yusuf et al., 2000) . Furthermore, B 2 R receptor activation can induce MAPK signalling (Fleming et al., 1995; Blaukat et al., 1999) , and activate phospholipase A 2 , liberating arachidonic acid and subsequently increasing prostaglandin synthesis (Leeb-Lundberg et al., 2005) . Activation of any or all of these signalling pathways may explain why bradykinin induces uterine contractions (Wassdal et al., 1998; Trzeciak et al., 2000) .
The majority of bradykinin actions are mediated through two G protein-coupled receptors (GPCR) termed B 1 and B 2 , which have little sequence homology (e.g. 36% for human bradykinin receptors). In general B 2 receptors (B 2 R) are constitutively expressed in most tissues including smooth muscle (Couture et al., 2001) , whereas, although B 1 expression is negligible in healthy cells its' expression is inducible, being dramatically enhanced as a result of tissue injury, infection, inflammation or anoxia (Marceau et al., 1998) ..
Despite activating many of the same signalling pathways, the kinetics of B 1 and B 2 receptor signalling are very different. B 2 R activation is typically transient, desensitizing rapidly (Faussner et al., 1998) , whilst B 1 receptor signalling is prolonged due to its relative insensitivity to phosphorylation and desensitization (Blaukat et al., 1999) . GPCR desensitization is typically mediated through the action of G protein-coupled receptor kinases (GRK), which phosphorylate agonist-occupied receptors at serine and/or threonine moieties (Willets et al., 2003) . GRK phosphorylation promotes the recruitment of arrestin proteins, whose binding physically blocks interaction of GPCR and G proteins, prior to promoting receptor internalisation (Lamb et al., 2001; Willets et al., 2003; DeWire et al., 2007) . Indeed, data from model cell systems indicate that B 2 R are substrates for several GRKs (Blaukat et al., 2001) . As GRK mediated phosphorylation promotes arrestin interaction, it is also not surprising that arrestin proteins are reported to regulate exogenously expressed B 2 R signalling in HEK293 cells (Zimmerman et al., 2011) . Previous data from rats highlight the presence of B 2 R on myometrial cells (Murone et al., 1999) , activation of which would explain why bradykinin induces uterine contractions (Wassdal et al., 1998; Trzeciak et al., 2000) . Notwithstanding these findings, presently little is known regarding the consequences of and regulatory mechanisms involved in bradykinin receptor signalling in the myometrium.
Here we show that bradykinin activates pro-contractile signalling pathways within the human myometrium, and characterise the molecular mechanisms underlying bradykinin receptor regulation.
Materials and methods

Cell culture
The immortalised human ULTR myometrial cell line (Perez-Reyes et al., 1992) was cultured in Dulbecco's minimal essential medium, supplemented with 10% foetal calf serum, penicillin (100 IUml -1 ), streptomycin (100 µgml -1 ), and amphotericin B (2.5 µgml -1 ) and
Glutamax-1. Cells were maintained under humidified conditions at 37C, in air/5% CO 2 .
siRNA targeted arrestin and GRK depletion
Endogenous arrestin2 or arrestin3 were targeted for depletion using the following previously characterised (Brighton et al., 2011a; Brighton et al., 2011b) siRNA constructs designed to target either human arrestin2 (ARRB1) (5'-GGAGAUCUAUUACCAUGGtt-3') or arrestin3 (ARRB2) siRNA (5'-CGAACAAGAUGACCAGGUAtt-3') (Ambion, Applied Biosystems, Warrington, UK). For MAPK and single cell imaging experiments ULTR cells (150,000 per well) were transfected with either negative control (non-targeting 100 nM), anti-arrestin2
(100 nM), or anti-arrestin3 (10 nM) siRNA constructs using the Interferin™ transfection reagent (Polyplus, NY, USA), as per manufacturers' instructions. Endogenous GRK proteins were targeted for depletion using the following previously characterised (Willets et al., 2009) siRNA constructs designed to target either GRK2 (5-GGCAGCCAGUGACCAAAAAtt-3),
(Ambion, Applied Biosystems, Warrington, UK) using the Interferin transfection reagent according to the manufacturer's instructions. h before transfection at a density of 10,000 cells per well and transfected with either negative control (100 nM), anti-human arrestin2 (100 nM) or anti-human arrestin3 (10 nM) siRNAs.
Assessment of agonist-stimulated
Transfection was achieved using Interferin™ transfection reagent (Polyplus, NY, USA), as per manufacturers' instructions. ] i levels were determined by increases in cytosolic fluorescence in a defined area of interest exactly as described previously (Willets et al., 2005; Willets et al., 2008) .
Determination of bradykinin
Bradykinin B 2 R desensitization was determined using techniques similar to our previously validated protocols (Willets et al., 2009; Brighton et al., 2011b) . Briefly, to assess receptor desensitization cells were stimulated with a maximal agonist concentration (bradykinin 1 M) for 30 sec (termed R1), followed by a 5 min wash period before a second 30 sec agonist challenge (100 nM, termed R2). Peak [Ca 2+ ] i R2 responses were significantly attenuated compared to R1 and the resulting reduction in the R2/R1 ratio is interpreted as an indication of receptor desensitization (Willets et al., 2009) . To determine whether arrestin proteins affected receptor desensitization, cells were transfected with either negative control (100 nM), arrestin2 (100 nM) or arrestin3 (10 nM) siRNAs for 48 h prior to experimentation as described above.
Detection of MAPK activation
Agonist-driven ERK1/2 activity was detected using Western blotting techniques as described previously (Brighton et al., 2009) . Agonist-stimulated p38 MAPK phosphorylation was also detected through a similar Western blotting approach (Brighton et al., 2011a samples, an antibody against total p38 (Cell Signaling, Madison, WI, USA). Immunoreactive bands were visualized and quantified as described above. pERK1/2 or phospho-p38 MAPK absorbance levels for each treatment were corrected for differences in total ERK1/2 immunoreactivity before being expressed as a percentage of the basal pERK1/2 immunoreactivity.
Cell migration studies
To assess the ability of bradykinin to stimulate ULTR cell motility a scratch assay was employed. Briefly, cells were seeded into 24 well plates (100,000 per well) and left for 24 h.
Cells were then serum starved for a further 24 h prior to scratching with a p-10 pipette tip.
Once scratched the cell monolayers were washed with phosphate buffered saline to remove cell debris before fresh serum free media was added. Each scratch was visualised using a Nikon (Surrey, UK) Eclipse TE2000U microscope (4x objective) and three random views photographed. Next, cells were treated with either bradykinin (1 M) or 10% foetal calf serum and after 6, 12 and 24 h the scratches were again photographed as described above.
Scratch widths were measured and calibrated against a graticule to determine actual distances travelled. Data are expressed as the distance that cells migrated during the time period or scratch closure in m. For siRNA knockout experiments cells were seeded at 50,000 per well and transfected with the appropriate siRNAs as described above the next day. After a further 24 h cells were starved for 24 h prior to experimentation.
Data analysis
All concentration-response curves were generated and EC 50 values determined using nonlinear regression analysis software Prism, version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Data were analyzed using One-way or Two-way ANOVA, followed by appropriate post-hoc testing (Excel 5.0, Microsoft, Redmond, WA). Significance was accepted when p<0.05. 
Results
Bradykinin mediated increases in [Ca
Characterisation of B 2 R desensitization and re-sensitization of PLC signalling
The time course of B 2 R desensitization and re-sensitization were examined at the level of PLC activity by using the Ca 2+ -sensitive dye Fluo4. Initial experiments showed B 2 Rstimulated increases in [Ca 2+ ] i diminished rapidly within 5 min, even in the continued presence of bradykinin (1 M; Figure 2A ). Therefore, to assess receptor desensitization, cells
were stimulated with a maximal bradykinin concentration (1 M) for 30 sec (termed R1), followed by a wash period (5, 10 or 15 min) and then a second bradykinin challenge (1 M, 
Effects of arrestin depletion on B 2 R desensitization
To assess whether arrestin depletion affected B 2 R-stimulated [Ca 2+ ] i signals and receptor desensitization, ULTR cells were transfected with either negative-control (100 nM), antiarrestin2 (100 nM), anti-arrestin3 (10 nM) or both anti-arrestin2 and anti-arrestin3 siRNAs.
In agreement with our previous findings (Brighton et al., 2011a) , siRNA-mediated arrestin knockdown produced >70% knockdown of targeted isoforms (Supplementary Figure 1) . 
Initially, agonist-stimulated changes in [Ca
Effects of GRK depletion on B 2 R desensitization
To assess whether depletion of individual GRK isoforms affected B 2 R desensitization we utilised our standard desensitization protocol (outlined above) to measure changes in bradykinin-stimulated [Ca 2+ ] i signals following transfection with either negative-control (100 nM), anti-GRK2 (10 nM), anti-GRK3 (100 nM), anti-GRK5 (100 nM) or anti-GRK6 (10 nM)
siRNAs. In agreement, with our previous findings (Willets et al., 2009 ) siRNA treatment produced specific knockdown of targeted isoforms by >70% (Supplementary Figure 1) . After knockdown of GRK2 or GRK3 R2 levels of bradykinin-stimulated [Ca 2+ ] i were markedly greater than those observed in negative-control transfected cells ( Figure 3C ,D), which is indicative of deceased B 2 R desensitization. In contrast, suppression of GRK5 or GRK6 expression failed to alter the R2/R1 ratio ( Figure 3D ), implying that their absence did not affect B 2 receptor desensitization. Collectively, these data suggest that GRK2 and GRK3 play a role in the desensitization of B 2 R-stimulated [Ca 2+ ] i signals.
Temporal profile of bradykinin-stimulated ERK1/2 and p38 MAPK signals
The effects of B 2 R activation of ERK1/2 and p38 MAPK signals were investigated using standard immunblotting techniques (Brighton et al., 2011a; Brighton et al., 2011b) . Initially, the temporal profile of bradykinin-stimulated ERK1/2 signalling was determined following the addition of maximal agonist concentration (1 M, data not shown). Bradykinin induced a
rapid, yet transient increase in ERK1/2 phosphorylation peaking at 3 min, which returned to basal levels within 5 min ( Figure 4A ,C). Similarly, p38 MAPK phosphorylation peaked at 3 min however the level of phosphorylation was more sustained and did not return to basal until 15 min ( Figure 4B ,C). Further investigation showed that bradykinin-stimulated ERK1/2 phosphorylation was attenuated following inhibition of calmodulin kinase, Src kinase, Ca 2+ -dependent PKCs and was also dependent on extracellular Ca 2+ (see Supplementary Figure 2 ).
Depletion of arrestin isoforms expression enhances ERK1/2 and p38 MAPK signalling
Arrestins have previously been reported to modulate MAPK signalling activated by various
GPCRs. Therefore we initially examined whether manipulation of arrestin expression would alter B 2 R-induced ERK1/2 phosphorylation in ULTR cells. Transfection of ULTR cells with negative-control siRNA had no effect on basal ERK1/2 phosphorylation levels (basal means  S.E.M. for negative-control, 8562  732 and non-transfected cells, 12263  2079), or the magnitude or time-course of bradykinin-stimulated ERK1/2 responses compared to nontransfected cells ( Figure 5A ,B). In contrast, knockdown of either arrestin enhanced not only the peak of bradykinin-stimulated ERK1/2 phosphorylation, but markedly enhanced and prolonged the signal ( Figure 5A ,B).
Following negative-control siRNA transfection, the magnitude and temporal prolife of bradykinin-stimulated p38 MAPK signals, and basal p38 MAPK phosphorylation levels were comparable to those found in non-transfected cells (basal means  S.E.M. for negativecontrol, 9326  3275 and non-transfected cells, 8042  2500). However, following siRNA depletion of arrestin2 peak p38 MAPK phosphorylation was enhanced over the first 10 min, post bradykinin challenge ( Figure 6A ,B). Moreover, depletion of arrestin3 resulted in a similar enhancement of bradykinin-stimulated p38 MAPK phosphorylation, which was sustained throughout the experiment ( Figure 6A ,B).
Bradykinin stimulates ULTR cell migration but not proliferation
Bradykinin signalling mediates a plethora of different physiological outcomes and has previously been reported to induce both migration and proliferation of various cells types (Figueroa et al., 2012) . Therefore, we utilised standard scratch-wound or [ 3 H]thymidine incorporation assays to examine whether bradykinin stimulated cell migration or proliferation, respectively. Initial studies showed that when compared to non-treated controls at 12 and 24 h, scratch closure was significantly enhanced in the presence of bradykinin ( Figure 7A ), and was prevented by the inclusion of the B 2 R specific antagonist HOE140 (Supplementary Figure 3) . Bradykinin-induced cell movement was approximately 50% less than that promoted by foetal calf serum (included as a positive control; Figure 7A ). Although foetal calf serum treatment doubled [ 3 H]thymidine incorporation measured 24 h after treatment, bradykinin had no effect, suggesting that bradykinin-induced scratch closure was due to cell movement and not proliferation (see Supplementary Figure 4 ).
Roles for ERK1/2, p38 and Rho in bradykinin-stimulated ULTR cell migration
GPCR-driven cell migration can be mediated through the activation of numerous downstream signalling pathways including MAPK and Rho kinase. Therefore, we utilised specific inhibitors of ERK1/2, p38 and Rho signalling to determine whether their recruitment was required for bradykinin-induced cell migration. Following inclusion of the MEK inhibitor PD98059 (20 M), bradykinin-stimulated ULTR cell migration was ablated ( Figure 7B ).
Moreover, addition of the p38 inhibitor SB203580 (20 M) not only blocked bradykininstimulated ULTR migration but attenuated cell migration below that seen in untreated cells ( Figure 7B ). Finally, inclusion of the ROCK inhibitor Y27632 (20 M) also attenuated bradykinin-stimulated, but not basal ULTR cell migration ( Figure 7C ).
Effects of arrestin depletion on B 2 R-driven cell migration
Collectively, our data suggest that ERK1/2, p38 MAPK and Rho kinase signalling, play roles in bradykinin-induced ULTR cell migration. Furthermore, depletion of arrestin protein expression enhances and prolongs B 2 R-stimulated MAPK signalling. Therefore, we examined whether manipulation of arrestin expression through siRNA knockdown could alter the rate of bradykinin-stimulated ULTR cell migration. In all our previous studies where siRNA techniques have been utilised to knockdown endogenous arrestin expression, maximal depletion of arrestin proteins occurred 48 h after transfection. However, since the duration of the scratch assays was 72 h, arrestin expression was determined in cells after the scratch experiments, to assess the effectiveness of the siRNA knockdown. Interestingly, 72 h after transfection with arrestin3 siRNA, knockdown of arrestin3 expression was similar to ( Figure   8A ,B) that previously observed 48 h post transfection (Brighton et al., 2011b) . Anti-arrestin2
siRNA produced marked suppression of arrestin2 expression, although the degree of knockdown was slightly less effective after 72 h, showing a 20% higher expression than when measured at 48 h (Brighton et al., 2011b) . Importantly, in both cases each arrestin siRNA appeared selective for the targeted isoform ( Figure 8A,B) . Comparison of nontransfected and negative-control siRNA transfected cells showed that ULTR cell migratory behaviour was unaltered. Suppression of arrestin2 expression had no effect upon basal ULTR cell migration, yet markedly enhanced migration after 24 h challenge with bradykinin ( Figure   8C ). In contrast, knockdown of arrestin3 had no effect upon bradykinin-stimulated cell movement, yet significantly increased basal cell motility measured at 12 and 24 h ( Figure   8C ). Depletion of both arrestins enhanced bradykinin-stimulated migration to similar levels as when arrestin2 expression was suppressed ( Figure 8C ).
Discussion
Although the exact cause of preterm birth is still unclear, its initiation is strongly correlated with the presence of intrauterine infection (Goldenberg et al., 2008) . In many ways this is unsurprising since spontaneous labour is associated with an increased synthesis and release of an array of pro-inflammatory agents, similar to that observed during infection (Agrawal et al., 2012) . Indeed, several pro-inflammatory agents (e.g. histamine and prostaglandins) are known uterotonins (Bytautiene et al., 2004b; Willets et al., 2008; Willets et al., 2009) , whilst others are reported to increase the expression of key elements of the myometrial contractile machinery (e.g. prostaglandin F 2 and oxytocin receptors; connexion 43; and cyclooxygenase 2) (Agrawal et al., 2012) . Moreover, the presence of the kallikein-kinin system in the human uterus (Clements et al., 1994) , suggests that bacterial infection is likely to enhance intrauterine bradykinin production. However, despite its central role in the inflammatory process little is currently known regarding the role that bradykinin plays in myometrial physiology. To rectify this shortfall, the effects of bradykinin-stimulation on the immortalised human myometrial ULTR cell-line were examined in this study. Our data show that bradykinin causes a concentration-dependent increase in [Ca 2+ ] i , which was blocked by the B 2 R selective antagonist HOE140. These findings support the notion that, as in the rat (Trzeciak et al., 2000) , bradykinin has the potential to stimulate human uterine contractions through activation of the B 2 R expressed on myometrial cells. Notwithstanding, its direct ability to induce PLC activity and hence likely myometrial contractions, bradykinin is also reported to stimulate mast cell degranulation (Heitsch, 2000) . Mast cell degranulation releases a plethora of inflammatory mediators, including histamine, which has been reported to induce myometrial contractions via the activation of H 1 histamine receptors (Bytautiene et al., 2004a) . Therefore, it is conceivable that bradykinin may have a multifunctional role in the uterus, not only acting as an uterotonin, but might also potentiate the contractile stimuli within the uterus.
In agreement with previous reports (Faussner et al., 1998) Increased cyclooxygenase 2 expression, accompanied by the subsequent increase in proinflammatory prostaglandins, is a key element required to switch the uterus from a quiescent to a contractile state prior to the onset of labour (Agrawal et al., 2012) . Moreover, MAPK signalling is reported to play a key role in the increased expression of cyclooxygenase 2 expression (Bartlett et al., 1999; Molnar et al., 1999) , highlighting their potential role in the control of prostaglandin production and labour induction. Despite evidence from model cell systems (Zimmerman et al., 2011) , and fibroblasts (Hayashi et al., 2000) suggesting that the B 2 R activates MAPK signalling, the ability of B 2 R to stimulate these pathways in myometrium has not previously been reported. In ULTR cells, ERK phosphorylation was transient, closely mirroring the duration of [Ca 2+ ] i signals, which underlies the Ca 2+ /calmodulin/PKC-dependent nature of bradykinin-stimulated ERK phosphorylation.
Contrastingly, p38 phosphorylation was more prolonged with a similar time-course to that previously observed in fibroblasts (Hayashi et al., 2000) . Interestingly, in fibroblasts bradykinin-induced p38 phosphorylation stimulates the production of two pro-inflammatory cytokines, interleukin (IL) 6 and IL8, both of which are strongly correlated to initiation of labour (Christiaens et al., 2008) . It is therefore conceivable that bradykinin may play a similar role in the myometrium during infections to help initiate labour. However, since the effects of MAPK activation on gene expression can be variable, further work is required to confirm a link between bradykinin signalling and alterations in contractile protein expression.
Accumulating evidence implicates arrestin proteins not only as regulators of GPCR desensitization and internalisation, but as multifunctional proteins serving as agonistregulated adaptor scaffolds, capable of directing downstream signalling events within cells (DeWire et al., 2007) . Indeed, arrestin3 but not arrestin2 has a well-documented role as an ERK1/2 scaffold, retaining ERK1/2 within the cytoplasm, prolonging its activation (DeWire et al., 2007) . In ULTR cells, suppression of either arrestin2 or arrestin3 produced a similar marked enhancement of the peak and plateau phases of bradykinin-stimulated ERK1/2 signalling. Since arrestin2 is incapable of directly scaffolding ERK1/2, it may be acting as previously described as a negative regulator of arrestin3-induced ERK1/2 signalling (Ahn et al., 2004) . However, and in contrast to our previous findings for oxytocin and histamine H 1 receptors (Brighton et al., 2011b) , it seems unlikely that arrestin3 is acting as a direct scaffold since ERK1/2 signalling is not diminished as expected following suppression of arrestin3 (Brighton et al., 2011b) , elevated p38 signalling is likely a consequence of the inability to promote B 2 R desensitization in the absence of arrestins.
Aside from activating PLC and MAPK signalling pathways, bradykinin is also reported to induce cellular proliferation and migration (Figueroa et al., 2012) . Herein, we report for the first time that bradykinin induces myometrial cell movement, but not proliferation. Although mediated through the activation of a plethora of different signalling pathways, in ULTR cells B 2 R-stimulated cell movement appears to be dependent on both p38 and ERK1/2 MAPKs, and Rho kinase signalling. Indeed, all three inhibitors block basal cell migration to varying degrees which may suggest that MAPK and Rho kinases play a role in agonist-independent ULTR cell movement. Furthermore, both arrestin2 and 3 have been implicated in the regulation of GPCR-mediated cell migration through a variety of mechanisms. For example, arrestin3 enhances, whilst arrestin2 inhibits Rho-dependent membrane blebbing, modulating cell movement via an actin-reliant mechanism (Godin et al., 2010) . The fact that B 2 R-driven cell movement is enhanced following arrestin2 knockdown, may support this role for arrestin3 in agonist-stimulated motility. However, the failure to inhibit migration in the absence of arrestin3 suggests that ULTR movement is also reliant on alternative mechanisms.
Recent evidence highlights a role for arrestin2 as the dominant scaffold for cofilin-specific phosphatase (Zoudilova et al., 2007) . Indeed, arrestin binding increases cofilin-specific phosphatase activity, leading to actin filament severing to promote cell movement in a G protein/Ca 2+ -independent manner (Zoudilova et al., 2007) . Our data both support and contradict such a role for arrestin2 in ULTR cells since in the absence of arrestin3 un-stimulated cell motility was enhanced, suggesting that arrestin2 may have more access to cofilin-specific phosphatase, thus promoting its action and cell movement. Conversely, as ULTR cell movement is unaltered in the absence of arrestin2 this would argue against this assumption. Although the arrestin-dependent mechanisms outlined above may play roles in agonist-mediated ULTR cell movement, evidence from HEK293 cells suggests that the answer may be far simpler. Indeed, expression of a mutant B 2 R which failed to recruit arrestin proteins, not only led to enhanced PLC, and ERK1/2 signalling, but increased cell motility (Zimmerman et al., 2011) . Therefore, it seems likely that a similar scenario occurs in ULTR cells, with increased B 2 R signalling underling increased motility, possibly regulated by arrestin2 more than 3.
Conclusion
In summary we show that bradykinin activates pro-contractile signalling pathways within human myometrial cells and arrestins play vital roles in regulating these signalling pathways.
Collectively, our data suggest that bradykinin not only acts as an utertonin but has the potential to enhance the contractile environment of the uterus, via activation of MAPK signalling. (1 µCi) was added to each of the wells and incubated for 4 hours. Media was then aspirated
